Opens in a new tab

Dr. Zhao Jianfu

Chinese name: 赵建夫
Professor, Chief Physician . Oncology
Dr. Zhao Jianfu is a professor, chief physician, and doctoral supervisor at the First Affiliated Hospital of Jinan University, where he serves as vice president and director of the Jinan University Cancer Diagnosis and Treatment Research Center. He specializes in immunotherapy and multimodal integrated treatment for advanced prostate cancer, massive liver cancer, and drug-resistant lung cancer.

Private & confidential

No obligation

Coordinated end-to-end by Orisene

More than 50
SCI publications
Over 30
Research projects led
More than 30
Academic awards won

  • The Physician

About Dr. Zhao Jianfu

Dr. Zhao Jianfu holds a PhD and serves as professor, chief physician, and doctoral supervisor at the First Affiliated Hospital of Jinan University (Guangzhou Overseas Chinese Hospital). He is vice president of the hospital and director of the Jinan University Cancer Diagnosis and Treatment Research Center, leading a Guangdong provincial key clinical specialty of oncology. His clinical and research work centers on immunotherapy combined with molecular targeted therapy for solid tumors. He pioneered multimodal integrated treatment for advanced prostate cancer and novel systemic therapies for massive liver cancer, publishing over 50 SCI papers and leading more than 30 research projects.
  1. Vice president of the First Affiliated Hospital of Jinan University and director of the Jinan University Cancer Diagnosis and Treatment Research Center.
  2. More than 20 years of clinical experience in oncology, focusing on immunotherapy combined with molecular targeted therapy for solid tumors.
  3. Has led over 30 research projects, including National Natural Science Foundation of China grants.
  4. Published more than 50 SCI papers, with 25 in top-tier journals, and holds 5 authorized invention patents.
  5. Recipient of more than 30 awards, including the China Industry-University-Research Collaboration Innovation Award and the second prize of the Ministry of Education Invention Award.
  6. Named among the Lingnan Famous Doctors and selected as a 2025 Top Ten Medical Influential Expert.

Dr. Zhao Jianfu ’s Three Key Areas of Expertise

Three areas of focused expertise, each supported by a deep subspecialty team, high case volumes and an English-speaking care pathway coordinated by Orisene.

Advanced Prostate Cancer

He specializes in immunotherapy combined with multimodal integrated treatment for advanced and metastatic prostate cancer, including bone and lung metastases. By combining immune activation, targeted therapy, and rehabilitation training, his approach has helped patients achieve long-term tumor-bearing survival and recovery of motor function.

Massive Liver Cancer

He developed new systemic treatment technology for massive and unresectable liver cancer, integrating targeted therapy, immunotherapy, radiotherapy, and radionuclide treatment. This multimodal strategy improves tumor control and survival for patients with this extremely difficult-to-treat malignancy, helping to extend overall survival and improve quality of life.

Drug-Resistant Lung Cancer

He focuses on reversing radioresistance and targeted-drug resistance in advanced lung cancer through nanomedicine-based radiosensitization and immune microenvironment remodeling, seeking to restore sensitivity to radiotherapy and improve clinical outcomes for patients with refractory disease, offering new hope for those who no longer respond to standard treatment.

More：Esophageal Cancer——immune checkpoint inhibitor therapy; Nasopharyngeal Carcinoma——immunotherapy and radiotherapy; Gastrointestinal Malignancies——integrated treatment; Tumor Rehabilitation——functional recovery and psychological support

  • Clinical Practice & Publications

Selected cases, research & publications

Representative work drawn from documented clinical treatments, publicly indexed literature, and hospital project records, reflecting the depth of this physician's hands-on expertise and academic rigor.
1. Zoledronic Acid and Thymosin α1 Immunotherapy for Advanced Prostate Cancer
This clinical and mechanistic study retrospectively analyzed patients with advanced or metastatic prostate cancer, showing that adding zoledronic acid and thymosin α1 to androgen deprivation therapy improved outcomes. It enhanced cytotoxic CD8-positive T cell infiltration and tumor inflammation, suppressing prostate cancer progression through the MyD88/NF-kB pathway.
2. Tellurium Nanotherapeutics Reversing Lung Cancer Radioresistance
By designing an EGFR and mitochondria dual-targeting tellurium-based radiosensitizer, this study overcame radiation resistance in lung cancer. The nanomedicine accumulated and penetrated tumor cells, enhanced X-ray sensitivity through reactive oxygen species production and mitochondrial dysfunction, and remodeled the tumor microenvironment, offering a promising strategy for precise clinical radiotherapy.
3. Expert Consensus on Immune Checkpoint Inhibitors for Esophageal Cancer (2025)
As a chief editor, Dr. Zhao contributed to the 2025 expert consensus on the whole-course management of immune checkpoint inhibitors for esophageal cancer. This authoritative guideline systematically covers pre-treatment evaluation, standardized administration and monitoring, post-treatment follow-up, and management of adverse reactions, promoting standardized immunotherapy for this high-incidence cancer in China.
4. Multidisciplinary Treatment Restoring Mobility in Advanced Prostate Cancer
A patient with advanced prostate cancer and multiple lung and spinal metastases had been bedridden with lower-limb paralysis for over half a year after visiting seven hospitals. Through immune activation, rehabilitation breathing training, and progressive resistance exercise, the team helped him walk normally within two months, with prostate-specific antigen returning to normal and over eight years of high-quality survival.
5. Clinical Outcomes of Combined Immunotherapy in Metastatic Prostate Cancer
A retrospective analysis of advanced prostate cancer cases found that combined zoledronic acid and thymosin α1 therapy reduced tumor area on MRI in most patients, lowered serum PSA and PAP levels, and increased peripheral CD3-positive and CD8-positive T cells, demonstrating improved responses to androgen deprivation therapy in these difficult cases.
6. Multimodal Integrated Oncology Care at Jinan University
Dr. Zhao leads a multidisciplinary oncology team focused on refractory tumors such as massive liver cancer, advanced prostate cancer, and drug-resistant lung cancer. Integrating radiotherapy, thermal therapy, radionuclide treatment, and immune microenvironment regulation, the center provides individualized, full-cycle care and was recognized as a leading provincial clinical specialty.
  • Affiliated Hospital

Where Dr. Zhao Jianfu practices

Guangzhou

The First Affiliated Hospital of Jinan University（Guangzhou Overseas Chinese Hospital）

Chinese name: 暨南大学附属第一医院（广州华侨医院）
The First Affiliated Hospital of Jinan University, Guangzhou Overseas Chinese Hospital, founded in 1978, is a Grade-A tertiary university hospital and Guangdong high-level hospital, one of the province's first internet hospitals, with cerebrovascular, joint-sports and bariatric centers serving 80,000 annual discharges.
Since 1981
45 years of care
1,969
Licensed beds
73,000
Annual inpatient surgeries
Yes
Licensed beds
View Hospital Profile
Appointments with this physician are booked through official hospital channels only, coordinated end-to-end by Orisene.
  • WHY INTERNATIONAL PATIENTS CHOOSE CHINA

Why patients travel to China for treatment

Six reasons international patients now put China on their shortlist — from internationally aligned clinical capability to the policy channels that make treatment here genuinely reachable.

Clinical capability at international standard

Chinese hospitals deliver internationally aligned protocols, performing vast volumes of advanced robotic, minimally invasive, and complex transplant surgeries annually. This massive clinical data and highly specialized workforce ensure world-class outcomes, even for rare and complex cases.

Diagnostics and treatment in days, not months

A full medical workup that typically means months of waiting elsewhere is completed in China within 48–72 hours. Imaging, labs, and multidisciplinary consultations are integrated into a single visit, allowing treatment to commence immediately.

Transparent, itemised pricing

Chinese healthcare offers legally binding, itemised cost estimates before treatment begins, eliminating hidden fees or surprise billing. Due to national centralized procurement, total expenses remain 40–70% lower than comparable care in Western Europe or North America.

Policy channels that open the door

China facilitates access through 240-hour visa-free transit and dedicated medical visa routes. Policies like the Greater Bay Area drug pathway and Boao Lecheng’s pilot zone allow designated hospitals to administer innovative therapies not yet globally approved.
  • International Patient Guide

Consulting this physician, step by step

From the first message to the follow-up after you fly home, one coordinator, no paperwork on your side.
01
Day 0
  • Share your story
    A private consultation with an Orisene advisor, by message, phone or video. Send medical records in any language. Nothing is shared with the hospital yet.
02
Days 1–3
  • Records review & matching
    Orisene translates and presents your case to the right specialist. The hospital returns a tailored care plan, with costs itemised once that plan is confirmed.
03
Days 3–7
  • Your consultation
    Appointments are booked through official hospital channels only. Your navigator accompanies every visit with real-time interpretation, so you can focus on one thing: being cared for.
04
After you fly home
  • Reports & follow-up
    Translated reports and prescriptions delivered within days, remote follow-up coordination with your physicians at home, and a standing line to your navigator.
Orisene offers English and multilingual services, a professional medical interpreter at every consultation, plus translation of your records, reports and prescriptions.

Ready to plan your consultation with Dr. Zhao Jianfu?

Send your records in any language. An Orisene advisor will reply within 2 hours, present your case to the right specialist, and return a tailored care plan with itemised costs, before anything is booked. Simple. Private. Efficient.
Contact

Confidential, permanently

Independent — no hospital commission

We never handle medical fees

Information Sources

This physician profile is compiled by the Orisene team from publicly available online sources and verified at the time of publication. Details may change, and physician availability is confirmed at the time of booking.

Disclaimer: This information is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personal medical guidance.

Mention of any specific product, brand, or manufacturer is for informational purposes only and does not constitute an endorsement or recommendation by Dr. Zhao Jianfu.